ARCHIVES

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

RFOs Available, Contract Awards, Sole Source Negotiations

February 3, 1978

Fogarty Leads Grant Program On World Tobacco Research.

July 6, 2001

More DCT Concepts Approved By Advisors

July 10, 1992

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Guest Editorial by Robert Cook-Deegan: Myriad Case Ruling Likely to Concur With DOJ Arguments

April 19, 2013

When Is A Cancer Cured? NCI Suggest One-Year Survival Rates Useful In Determining Advances

August 1, 1975